Daiying Zuo

11PUBLICATIONS
6CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesBiologically active moleculesMolecular medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Feb 03, 2026
20(R)-Ginsenoside Rg3 Suppresses P-Glycoprotein-Mediated Multidrug Resistance in A549/Taxol Cells by Targeting MDM2-IκB-α Signaling Axis.

Yuying Yang, Wenhui Zhang, Zhehao Xie

|Sep 25, 2024
EML4-ALK G1202R and EML4-ALK L1196M mutations induce crizotinib resistance in non-small cell lung cancer cells through activating epithelial-mesenchymal transition mediated by MDM2/MEK/ERK signal axis.

Yuying Yang, Huan Yang, Yunhui Gao

|Jul 30, 2024
SIRT1 silencing promotes EMT and Crizotinib resistance by regulating autophagy through AMPK/mTOR/S6K signaling pathway in EML4-ALK L1196M and EML4-ALK G1202R mutant non-small cell lung cancer cells.

Qian Yang, Keyan Sun, Tianyu Gao

|Dec 27, 2023
CD74-ROS1 L2026M mutant enhances autophagy through the MEK/ERK pathway to promote invasion, metastasis and crizotinib resistance in non-small cell lung cancer cells.

Xiaobo Xu, Ye Li, Rui Xu

|Dec 28, 2022
FAT4 activation inhibits epithelial-mesenchymal transition (EMT) by promoting autophagy in H2228/Cer cells.

Yuying Yang, Yang Li, Qian Yang

|Jun 22, 2021
W436, a novel SMART derivative, exhibits anti-hepatocarcinoma activity by inducing apoptosis and G2/M cell cycle arrest in vitro and in vivo and induces protective autophagy.

Shuai Man, Zhuzhu Wu, Rui Sun

Pageof 2

Frequent Collaborators

2 joint publications

Yingliang Wu

1 joint publications

Jiahui Cui

1 joint publications

Xing Chang

1 joint publications

Wenfeng Gou